Kala’s Third Phase III Trial Should Line Up Approval In Dry Eye
Executive Summary
Data showing that endpoints were met for both signs and symptoms of dry eye disease should position Kala’s KRI-121 for US approval. The company hopes to differentiate with short-term flare treatment.